Immunology and inflammation

News

Earendil raises $787m as lead TL1A antibody starts phase 2

Earendil has raised an impressive $787m in financing for its AI-powered drug platform, attracting yet more buy-in from Sanofi.

News

J&J gets FDA okay for psoriasis drug icotrokinra

Johnson & Johnson's much-anticipated oral IL-23 drug, icotrokinra, has claimed FDA approval as Icotyde for first-line treatment of plaque psoriasis.

News

Cancer risk scuppers Kyowa Kirin's autoimmune disease drug

Kyowa Kirin has terminated all clinical trials of its anti-OX40L antibody rocatinlimab, after cases of cancer were seen in patients taking the drug.

News

Boehringer bets up to $500m on Sitryx immunology programme

Boehringer Ingelheim's partnership with Sitryx is focused on a family of small-molecule drugs for autoimmune and inflammatory diseases.

News

Novartis' oral BTK drug moves the needle in CINDU

Novartis is set to expand the label for its oral BTK inhibitor Rhapsido, keeping the drug on course to become one of its biggest-ever brands.

News

Takeda signs $1.7bn AI alliance with Iambic

Iambic bags another pharma partner, Takeda, which plans to use its AI platform to find drugs for cancer, gastrointestinal, and inflammatory disorders.

Earendil raises $787m as lead TL1A antibody starts phase 2

J&J gets FDA okay for psoriasis drug icotrokinra

Cancer risk scuppers Kyowa Kirin's autoimmune disease drug

Boehringer bets up to $500m on Sitryx immunology programme

Novartis' oral BTK drug moves the needle in CINDU

Takeda signs $1.7bn AI alliance with Iambic

Roche adds another obesity drug with $1.16bn Rona deal

Discover a new era of healthcare panel engagement: Grounded ...

Immunology and inflammation

Editor's Picks